Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity.
Explore how engineered extracellular vesicles can enhance antigen-specific regulatory T cells to improve immune response.
A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has ...
AZoLifeSciences on MSN
Engineered EVs offer a modular and clinically adaptable immune-tolerance platform
A research team at the Nano Life Science Institute (WPI-NanoLSI) and the Faculty of Medicine at Kanazawa University has ...
Study introduces TRACeR-I, a protein platform with broad HLA compatibility, paving the way for advanced immune response engineering and disease-specific targeting. Study: Targeting peptide antigens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback